[go: up one dir, main page]

ITRM20080529A1 - USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS. - Google Patents

USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS.

Info

Publication number
ITRM20080529A1
ITRM20080529A1 IT000529A ITRM20080529A ITRM20080529A1 IT RM20080529 A1 ITRM20080529 A1 IT RM20080529A1 IT 000529 A IT000529 A IT 000529A IT RM20080529 A ITRM20080529 A IT RM20080529A IT RM20080529 A1 ITRM20080529 A1 IT RM20080529A1
Authority
IT
Italy
Prior art keywords
chinurenine
prevention
derivatives
treatment
type
Prior art date
Application number
IT000529A
Other languages
Italian (it)
Inventor
Francesca Fallarino
Ursula Grohmann
Paolo Puccetti
Original Assignee
Uni Degli Studi Perugia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Uni Degli Studi Perugia filed Critical Uni Degli Studi Perugia
Priority to IT000529A priority Critical patent/ITRM20080529A1/en
Priority to PCT/IT2009/000451 priority patent/WO2010041288A1/en
Publication of ITRM20080529A1 publication Critical patent/ITRM20080529A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT000529A 2008-10-07 2008-10-07 USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS. ITRM20080529A1 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
IT000529A ITRM20080529A1 (en) 2008-10-07 2008-10-07 USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS.
PCT/IT2009/000451 WO2010041288A1 (en) 2008-10-07 2009-10-06 Use of l-kynurenine and derivatives thereof for the prevention and treatment of diabetes mellitus type 1

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IT000529A ITRM20080529A1 (en) 2008-10-07 2008-10-07 USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS.

Publications (1)

Publication Number Publication Date
ITRM20080529A1 true ITRM20080529A1 (en) 2010-04-08

Family

ID=40651158

Family Applications (1)

Application Number Title Priority Date Filing Date
IT000529A ITRM20080529A1 (en) 2008-10-07 2008-10-07 USE OF L-CHINURENINE AND ITS DERIVATIVES FOR THE PREVENTION AND TREATMENT OF TYPE 1 DIABETES MELLITUS.

Country Status (2)

Country Link
IT (1) ITRM20080529A1 (en)
WO (1) WO2010041288A1 (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102258020B (en) * 2011-06-14 2013-06-12 北京大学 Micromolecule inhibitor containing growth hormone TAA1 synthetic pathway capable of inhibiting ethylene induction
EP3197466B1 (en) * 2014-09-26 2021-02-17 The University Of British Columbia A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation
WO2018044724A1 (en) 2016-08-31 2018-03-08 Ampio Pharmaceuticals, Inc. Treatment of disease with n-acetyl kynurenine

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016549A2 (en) * 2000-08-25 2002-02-28 Yeda Research And Development Co. Ltd. METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002016549A2 (en) * 2000-08-25 2002-02-28 Yeda Research And Development Co. Ltd. METHODS OF TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES WITH CpG-CONTAINING POLYNUCLEOTIDE
EP1369114A1 (en) * 2002-06-07 2003-12-10 Peter Priv. Doz. Dr. Terness Use of tryptophan metabolites as pharmaceutical agents

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
CONNICK J H ET AL: "The role of kynurenines in diabetes mellitus", MEDICAL HYPOTHESES, EDEN PRESS, PENRITH, US, vol. 18, no. 4, 1 December 1985 (1985-12-01), pages 371 - 376, XP023026196, ISSN: 0306-9877, [retrieved on 19851201] *
QUINTANA F J ET AL: "VACCINATION WITH EMPTY PLASMID DNA OR CPG OLIGONUCLEOTIDE INHIBITS DIABETES IN NONOBESE DIABETIC MICE: MODULATION OF SPONTANEOUS 60-KDA HEAT SHOCK PROTEIN AUTOIMMUNITY", JOURNAL OF IMMUNOLOGY, AMERICAN ASSOCIATION OF IMMUNOLOGISTS, US, vol. 165, 1 January 2000 (2000-01-01), pages 6148 - 6155, XP002909778, ISSN: 0022-1767 *

Also Published As

Publication number Publication date
WO2010041288A1 (en) 2010-04-15

Similar Documents

Publication Publication Date Title
CL2007002841A1 (en) COMPOUNDS DERIVED FROM INDOL, ANTIGONISTS OF THE GLUCAGION RECEIVER; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; AND ITS USE TO TREAT MELLITUS TYPE 2 DIABETES, HYPERGLUCEMIA, DIABETES OR INSULIN RESISTANCE.
CL2014000801A1 (en) Variant of human fibroblast growth factor 21 (fgf21); pharmaceutical composition that includes it; and its use to treat type 2 diabetes, obesity, dyslipidemia, metabolic syndrome or any combination thereof.
CL2007002207A1 (en) COMPOUNDS DERIVED FROM SULFONYLAMINES; PHARMACEUTICAL COMPOSITION; AND USE OF COMPOUNDS IN THE TREATMENT OF GLAUCOMA.
CL2008001076A1 (en) COMPOUNDS DERIVED FROM SULFONAMIDE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2012003026A1 (en) Pharmaceutical composition comprising pioglitazone and linagliptin; preparation procedure; Use in the treatment of type 2 diabetes or obesity.
CL2009000309A1 (en) Aromatic fluoroglycoside derivatives, pharmaceutical composition containing these compounds, procedure to prepare it and its use in the treatment of type 1 and type 2 diabetes.
CL2011003350A1 (en) Nitrogenous heterocycle derivative compounds, pkm2 modulators; pharmaceutical composition comprising them; and its use in the treatment of cancer.
CL2012001321A1 (en) Compounds derived from spiro inden (or indan) -1,4-piperidin or spiro indolin-3,4-piperidin, gpr40 activators; pharmaceutical composition comprising them; and its use in the treatment of diabetes.
CL2007001022A1 (en) COMPOUNDS DERIVED FROM 1H-INDOL-2-CARBOXAMIDE; PREPARATION PROCEDURE, PHARMACEUTICAL COMPOSITION; AND USE FOR THE TREATMENT AND / OR PREVENTION OF DISEASES ASSOCIATED WITH THE MODULATION OF H3 RECEPTORS AS OBESITY, TYPE II DIABETES AND
CL2011001299A1 (en) Compounds derived from benzothiazoles; pharmaceutical composition; and its use as raf inhibitors for the treatment or prophylaxis of cancer.
CL2008003546A1 (en) Pyridine derived compounds; preparation procedure; pharmaceutical composition of said compounds; and use in the treatment and / or prophylaxis of type I and / or type II diabetes mellitus.
UY31596A1 (en) NEW INSULIN DERIVATIVES WITH EXTREMELY DELAYED TIME / ACTION PROFILE
CL2007000806A1 (en) COMPOUNDS DERIVED FROM REPLACED HETEROPENTACICLOS; PREPARATION PROCESS; INTERMEDIARY COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF CANCER.
CL2011001497A1 (en) Compounds derived from heterocycles, gpr120 modulator; pharmaceutical composition; and its use for the treatment of type I, ii diabetes and metabolic syndrome.
CL2011003266A1 (en) Compounds derived from imidazolidin-2-one, with inhibitory activity of 17alpha-hydroxylase / lyase-c17,20; pharmaceutical composition comprising them; and use in the treatment of inflammation or cancer, among others.
CL2007002327A1 (en) COMPOUNDS DERIVED FROM REPLACED FENIL-IMIDAZOL; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF HCV.
CL2007003520A1 (en) COMPOUNDS DERIVED FROM HETEROCICLES REPLACED WITH MORFOLINA, INHIBITORS OF THE PI3 QUINASA ACTIVITY; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUNDS; PHARMACEUTICAL KIT; AND ITS USE FOR CANCER PROFILACTIC OR THERAPEUTIC TREATMENT.
BRPI0909639A2 (en) Carbohydrate bar and its use
CL2007003614A1 (en) COMPOUNDS DERIVED FROM SULFONIL-FENIL-2H- [1,2,4] OXADIAZOL-5-ONA; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; PREPARATION PROCEDURE; AND USE OF THE COMPOUND IN THE TREATMENT OF METABOLISM DISORDERS, AS DIABETES MELLITUS, DIS
BRPI0814593A2 (en) COMPOUND, PHARMACEUTICAL COMPOSITION CONTAINING AND USE OF THE COMPOUND.
CL2006003672A1 (en) COMPOUNDS DERIVED FROM PIRIMIDO- [4,5-B] -OXAZINAS; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION THAT INCLUDES SUCH COMPOUND; AND USE OF THE COMPOUND IN THE TREATMENT OF MELLITUS DIABETES AND / OR OBESITY.
BR112012004335A2 (en) compound, pharmaceutical composition, and use of the compound.
CL2008003473A1 (en) Heterocycle substituted phenylpiperidine derivative compounds; preparation procedure; pharmaceutical composition comprising it; and use in the treatment of cardiovascular, thromboembolic and tumor disorders; in vitro uses.
BRPI0922233A2 (en) compounds, pharmaceutical compositions and methods for use in the treatment of metabolic syndromes.
CR20110100A (en) NEW DERIVATIVES OF SULFAMIDE REPLACED